Study protocol: The INTERMAP China Prospective (ICP) study

Abstract
Background: Unfavourable blood pressure (BP) level is an established risk factor for cardiovascular diseases (CVD), while the exact underlying reasons for unfavourable BP are poorly understood. The INTERMAP China Prospective (ICP) Study is a prospective cohort to investigate the relationship of environmental and nutritional risk factors with key indicators of vascular function including BP, arterial stiffness, and carotid-intima media thickness. Methods: A total of 839 Chinese participants aged 40-59 years from three diverse regions of China were enrolled in INTERMAP in 1997/98; data collection included repeated BP measurements, 24-hour urine specimens, and 24-hour dietary recalls. In 2015/16, 574 of these 839 persons were re-enrolled along with 208 new participants aged 40-59 years that were randomly selected from the same study villages. Participant’s environmental and dietary exposures and health outcomes were assessed in this open cohort study, including BP, 24-hour dietary recalls, personal exposures to air pollution, grip strength, arterial stiffness, carotid-media thickness and plaques, cognitive function, and sleep patterns. Serum and plasma specimens were collected with 24-hour urine specimens. Discussion: Winter and summer assessments of a comprehensive set of vascular indicators and their environmental and nutritional risk factors were conducted with high precision. We will leverage advances in exposome research to identify biomarkers of exposure to environmental and nutritional risk factors and improve our understanding of the mechanisms and pathways of their hazardous cardiovascular effects. The ICP Study is observational by design, thus subject to several biases including selection bias (e.g., loss to follow-up), information bias (e.g., measurement error), and confounding that we sought to mitigate through our study design and measurements. However, extensive efforts will apply to minimize those limitations (continuous observer training, repeated measurements of BP, standardized methods in data collection and measurements, and on-going quality control).
Funding Information
  • National Natural Science Foundation of China (81473044)
  • National Heart, Lung, and Blood Institute (R01-HL50490, R01-HL65461)
  • Environmental Protection Agency (83542201)
  • King’s College London
  • Canadian Institutes of Health Research (137535, PJT148697)
  • Wellcome Trust (103906)
  • Northern Ireland Chest, Heart and Stroke Association (R2019EPH)
  • Ministry of Education, Culture, Sports, Science and Technology (090357003)
  • Peking University
  • National Heart, Lung, and Blood Institute (R01-HL135486)
  • National Heart, Lung, and Blood Institute (R01-HL84228)
  • the West Midlands National Health Service Research and Development, UK